Ticker > Company >

Torrent Pharma share price

Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM BSE: 500420 SECTOR: Pharmaceuticals & Drugs  144k   280   25

3241.75
-9.10 (-0.28%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 3259.9

Today's Low

₹ 3184.1

52 Week High

₹ 3589.95

52 Week Low

₹ 2755

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

109715.55 Cr.

Enterprise Value

112939.75 Cr.

No. of Shares

33.84 Cr.

P/E

58.11

P/B

14.45

Face Value

₹ 5

Div. Yield

0.98 %

Book Value (TTM)

₹  224.33

CASH

108.76 Cr.

DEBT

3332.96 Cr.

Promoter Holding

68.31 %

EPS (TTM)

₹  55.78

Sales Growth

10.89%

ROE

20.43 %

ROCE

20.96%

Profit Growth

29.07 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Torrent Pharmaceuticals Ltd.

Losar Shelcal Molnutor Alprax Ampoxin Arkamim Azulix Chymoral Dilzem Nebicard Nexpro Nikoran Regestrone Unienzyme Veloz Styptovit Finast Dynapress Regestrone Pregachieve

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year10.89%
3 Year9.77%
5 Year8.17%

Profit Growth

1 Year29.07%
3 Year6.05%
5 Year12.73%

ROE%

1 Year20.43%
3 Year17.63%
5 Year18.36%

ROCE %

1 Year20.96%
3 Year18.67%
5 Year17.39%

Debt/Equity

0.4881

Price to Cash Flow

37.92

Interest Cover Ratio

7.3245

CFO/PAT (5 Yr. Avg.)

1.90848532215299

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 68.31 0.00
Dec 2024 68.31 0.00
Sep 2024 71.25 0.00
Jun 2024 71.25 0.00
Mar 2024 71.25 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 31.85978976395% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 4.26339999999999 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.90848532215299.
  • The company has a high promoter holding of 68.31%.

 Limitations

  • The company has shown a poor profit growth of 6.04905724790707% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.77390563268261% for the Past 3 years.
  • The company is trading at a high PE of 58.11.
  • The company is trading at a high EV/EBITDA of 31.1784.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2143 2438 2434 2377 2433
Total Expenditure 1427 1539 1513 1490 1565
Operating Profit 716 899 921 887 868
Other Income 76 21 -7 3 15
Interest 67 64 54 48 47
Depreciation 195 189 190 191 190
Exceptional Items 0 0 0 0 -24
Profit Before Tax 530 667 670 651 622
Tax 120 198 210 166 148
Profit After Tax 410 469 460 485 474
Adjusted EPS (Rs) 12.11 13.86 13.59 14.33 14

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6168.44 6450.57 6742.32 7695.2 8532.9
Total Expenditure 4251.45 4258.84 4641.6 5230.04 5643.73
Operating Profit 1916.99 2191.73 2100.72 2465.16 2889.17
Other Income 236.93 118.34 204.21 81.88 91.49
Interest 430.49 334.12 236.29 297.68 303.04
Depreciation 606.66 609.84 602.43 672.34 761.05
Exceptional Items 0 0 0 0 0
Profit Before Tax 1116.77 1366.11 1466.21 1577.02 1916.57
Tax 178.26 228.26 474.76 525.63 559.49
Net Profit 938.51 1137.85 991.45 1051.39 1357.08
Adjusted EPS (Rs.) 27.73 33.62 29.29 31.06 40.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 84.62 84.62 84.62 169.23 169.23
Total Reserves 5036.35 5945.48 6260.8 6286.73 6659.53
Borrowings 3139.99 2941.07 1971.6 2331.78 1603.78
Other N/C liabilities 168.27 175.74 412.18 675.04 955.45
Current liabilities 3387.48 2585.8 2423.36 3409.15 2988.6
Total Liabilities 11816.71 11732.71 11152.56 12871.93 12376.59
Assets
Net Block 7197.5 6741.24 6251.25 7971.85 7985.92
Capital WIP 513.33 554.84 543.54 674.9 203.94
Intangible WIP 23.08 33.27 23.96 23.03 22.29
Investments 134.87 174.87 183.66 205.12 322.27
Loans & Advances 100.91 75.61 65.3 68.42 95.24
Other N/C Assets 27.76 11 151.45 1.53 5.87
Current Assets 3819.26 4141.88 3933.4 3927.08 3741.06
Total Assets 11816.71 11732.71 11152.56 12871.93 12376.59
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1116.77 1366.11 1466.21 1577.02 1916.57
Adjustment 857.08 884.8 827.91 990.49 957.61
Changes in Assets & Liabilities -187.25 -468.12 86.25 -29.64 343.6
Tax Paid -206.7 -209.9 -240.27 -272.46 -324.68
Operating Cash Flow 1579.9 1572.89 2140.1 2265.41 2893.1
Investing Cash Flow 269.43 -316.28 -159.7 -2325.75 -296.07
Financing Cash Flow -1555.48 -1581.2 -1977.27 80.74 -2577.57
Net Cash Flow 293.85 -324.59 3.13 20.4 19.46

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 71.25 71.25 71.25 68.31 68.31
torrent investments limit... - - - - 68.31
torrent investments priva... 71.25 71.25 71.25 68.31 -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 28.75 28.75 28.75 31.69 31.69
investor education and pr... 0.11 - 0.11 0.11 0.11
nps trust - - 1.32 1.58 1.80
investor education and pr... - 0.11 - - -
kotak mahindra trustee co... 1.02 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit ICRA
Credit ICRA
Credit ICRA
Credit ICRA
Credit FIFTCH
Credit ICRA
Credit ICRA
Credit FITCH
Credit ICRA
Credit FITCH
Credit FITCH
Credit ICRA
Credit FITCH
TYPE AGENCY ACTION
Research BP Wealth
Research ICICI Securities Limited
Research Motilal Oswal
Research Reliance Securities
Research IDBI Capital

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY22
Concall Q3FY25
Concall Q3 FY20
Concall Q2FY21
Concall Q1FY24
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER ACTION
Presentation Q4FY21
Presentation Q2FY21

Company News

Torrent Pharma Stock Price Analysis and Quick Research Report. Is Torrent Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Torrent Pharma and its performance over the period of time. Torrent Pharma stock price today is Rs 3252.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Torrent Pharma cash from the operating activity was Rs 2893.1 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Torrent Pharma has a Debt to Equity ratio of 0.4881 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Torrent Pharma , the EPS growth was 29.0749 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Torrent Pharma has OPM of 33.8591803490021 % which is a good sign for profitability.
     
  • ROE: Torrent Pharma have a healthy ROE of 20.4307 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Torrent Pharma is Rs 3252.5. One can use valuation calculators of ticker to know if Torrent Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Torrent Pharma
X